Prognostic significance of 68Ga-Pentixafor PET/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET/CT and laboratory results

Kuyumcu, Serkan; Işık, Emine Göknur; Tiryaki, Tarık Onur; Has-Simsek, Duygu; Şanlı, Yasemin; Büyükkaya, Fikret; Özkan, Zeynep Gözde; Kalayoğlu-Beşışık, Sevgi; Ünal, Sabri

doi:10.1007/s12149-021-01652-1

Cited by 25 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mortality of patients with light chain MM exhibited significantly higher and the level of serum albumin was lower than other types (23). Similarly, it is believed that OS and the level of b2-MG were negatively correlated (r = −0.511, p = 0.01) (24). Our results are consistent with these previous studies; in our results, albumin and b2-MG levels were independent factors affecting PFS and OS.…”

Section: Discussionsupporting

confidence: 92%

The Apparent Diffusion Coefficient of Diffusion-Weighted Whole-Body Magnetic Resonance Imaging Affects the Survival of Multiple Myeloma Independently

et al. 2022

View full text Add to dashboard Cite

BackgroundDiffusion-weighted whole-body MRI (DW-MRI) is increasingly used to evaluate bone diseases of multiple myeloma (MM), but there is lack of quantitative indicator for DW-MRI to reflect the prognosis of MM. Apparent diffusion coefficient (ADC) values in DW-MRI has potential correlations between some indexes of MM, but the influence of ADC on MM survival needs to be further verified.MethodsA total of 381 newly diagnosed MM patients were enrolled in the study to analyze the effect of ADC values in DW-MRI on progression-free survival (PFS) and overall survival (OS). The Kaplan–Meier method was used to perform univariate survival analysis, and the Cox proportional hazards model was used for multivariate analysis. In addition to the ADC value, genetic and serological indexes were also included.ResultsThe survivals were observed in univariate ADC stratification with median PFS of 52.0, 45.0, 34.0, and 26.0 months (the unit of ADC value was 10−3 mm2/s; the ADC ranges were ADC < 0.4886, 0.4886 ≤ ADC < 0.6545, 0.6545 ≤ ADC < 0.7750, and ADC ≥ 0.7750; 95% CI, 43.759–62.241, 46.336–53.664, 39.753–46.247, and 27.812–32.188). The OS were 81.0, 61.0, 47.0, and 36.0 months (p < 0.001; 95% CI, 71.356–82.644, 67.630–70.370, 57.031–60.969, and 36.107–43.893). In Cox proportional hazards model, the ADC value was considered to be an independent risk factor affecting PFS and OS of MM (both p < 0.001).ConclusionsThis study supports that ADC in DW-MRI may independently stratify MM patients and better predict their prognosis. The combined use of DW-MRI and other parameters allows more accurate evaluation of MM survival.Trial Registrationhttp://www.chictr.org.cn/showproj.aspx?proj=49012, ChiCTR2000029587.

show abstract

Section: Discussionsupporting

confidence: 92%

The Apparent Diffusion Coefficient of Diffusion-Weighted Whole-Body Magnetic Resonance Imaging Affects the Survival of Multiple Myeloma Independently

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Such promising results were recently expanded by Kuyumcu et al, who enrolled 24 MM patients to investigate the predictive performance of PEN (35). In line with existing literature, increasing PET-based CXCR4 positivity was linked to reduced overall survival, an observation that was more pronounced than the correlation of FDG with that parameter (35).…”

Section: Novel Radiotracers [ 68 Ga]pentixafor (Pen)mentioning

confidence: 71%

Molecular Imaging in Multiple Myeloma—Novel PET Radiotracers Improve Patient Management and Guide Therapy

et al. 2022

View full text Add to dashboard Cite

Due to its proven value in imaging of multiple myeloma (MM), including staging, prognostication, and assessment of therapy response, 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) is utilized extensively in the clinic. However, its accuracy is hampered by imperfect sensitivity (e.g., so-called FDG-negative MM) as well as specificity (e.g., inflammatory processes), with common pitfalls including fractures and degenerative changes. Novel approaches providing a read-out of increased protein or lipid membrane syntheses, such as [11C]methionine and [11C]choline or the C-X-C motif chemokine receptor 4-targeting radiotracer [68Ga]Pentixafor, have already been shown to be suitable adjuncts or alternatives to FDG. In the present focused review, those imaging agents along with their theranostic potential in the context of MM are highlighted.

show abstract

“…In MM, CXCR4-targeted PET imaging using [ 68 Ga]Pentixafor has been demonstrated to yield complementary as well as superior results in both newly diagnosed as well as advanced disease compared to [ 18 F]FDG-PET [7][8][9]. Of note, marked inter-as well as intra-individual differences of receptor expression as a sign of clonal heterogeneity [10] and dynamic receptor regulation [11] have been observed, requiring further research to gain a deeper understanding of the underlying biology.…”

Section: Cxcr4-targeted Theranostics In Cancer and Its Limitations 21 Cxcr4-targeted Pet Imagingmentioning

confidence: 99%

In Vivo Targeting of CXCR4—New Horizons

Schottelius

Herrmann

Lapa

2021

Cancers

View full text Add to dashboard Cite

Given its pre-eminent role in the context of tumor cell growth as well as metastasis, the C-X-C motif chemokine receptor 4 (CXCR4) has attracted a lot of interest in the field of nuclear oncology, and clinical evidence on the high potential of CXCR4-targeted theranostics is constantly accumulating. Additionally, since CXCR4 also represents a key player in the orchestration of inflammatory responses to inflammatory stimuli, based on its expression on a variety of pro- and anti-inflammatory immune cells (e.g., macrophages and T-cells), CXCR4-targeted inflammation imaging has recently gained considerable attention. Therefore, after briefly summarizing the current clinical status quo of CXCR4-targeted theranostics in cancer, this review primarily focuses on imaging of a broad spectrum of inflammatory diseases via the quantification of tissue infiltration with CXCR4-expressing immune cells. An up-to-date overview of the ongoing preclinical and clinical efforts to visualize inflammation and its resolution over time is provided, and the predictive value of the CXCR4-associated imaging signal for disease outcome is discussed. Since the sensitivity and specificity of CXCR4-targeted immune cell imaging greatly relies on the availability of suitable, tailored imaging probes, recent developments in the field of CXCR4-targeted imaging agents for various applications are also addressed.

show abstract

Prognostic significance of 68Ga-Pentixafor PET/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET/CT and laboratory results

Cited by 25 publications

References 28 publications

The Apparent Diffusion Coefficient of Diffusion-Weighted Whole-Body Magnetic Resonance Imaging Affects the Survival of Multiple Myeloma Independently

The Apparent Diffusion Coefficient of Diffusion-Weighted Whole-Body Magnetic Resonance Imaging Affects the Survival of Multiple Myeloma Independently

Molecular Imaging in Multiple Myeloma—Novel PET Radiotracers Improve Patient Management and Guide Therapy

In Vivo Targeting of CXCR4—New Horizons

Contact Info

Product

Resources

About